Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
132 hedge funds and large institutions have $236M invested in Orexigen Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 51 increasing their positions, 41 reducing their positions, and 42 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 41
11% less call options, than puts
Call options by funds: $3.13M | Put options by funds: $3.52M
18% less funds holding
Funds holding: 161 → 132 (-29)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
58% less capital invested
Capital invested by funds: $566M → $236M (-$330M)
67% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14.9M |
| 2 |
Renaissance Technologies
New York
|
+$8.09M |
| 3 |
Morgan Stanley
New York
|
+$3.79M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.21M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$26.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$11.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.95M |
| 5 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
-$4.54M |
OREX Hedge Fund Activity: Q3 2015 in Review
132 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q3 2015, worth a combined $236M — down 58% from $566M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of OREX and 14 opened new positions — a net loss of 28 holders — while 41 trimmed existing stakes and 51 added.
The largest buyer was State Street, adding an estimated $14.9M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $26.1M sold.
- 132 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q3 2015, down from 161 in Q2 2015.
- Funds reported $236M of Orexigen Therapeutics, Inc. stock for Q3 2015, down 58% quarter-over-quarter.
- 14 funds opened new Orexigen Therapeutics, Inc. positions in Q3 2015 and 42 closed out, a net change of -28 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q3 2015 was State Street, an estimated $14.9M added.
- The largest Orexigen Therapeutics, Inc. seller in Q3 2015 was PFM Health Sciences, an estimated $26.1M sold.
Based on aggregated 13F filings for Q3 2015.